

Report on Invasive Pneumococcal Disease


Invasive pneumococcal disease (IPD) has become a notifiable disease since 9 January 2015. Isolation of *Streptococcus pneumoniae* from a normally sterile site or detection of *Streptococcus pneumoniae* DNA from a normally sterile site of a clinically compatible case are considered as laboratory confirmation criteria for IPD.

Report on IPD is a monthly report produced by the Communicable Disease Branch of the Centre for Health Protection (CHP), the Department of Health (DH). It summarizes the surveillance findings of IPD cases reported to the CHP.

Reporting period: 1 - 31 March 2023 (information as of 13 April 2023)

Number of IPD reported during the reporting period: 6

Graph 1. Number of IPD reported from January 2015 to March 2023 by month



Graph 2. Number of IPD reported from January 2015 to March 2023 by age group








Table 1. Number of IPD cases by age group and type of specimen in this reporting period

Specimen	< 2 years	2 to 4 years	5 to 17 years	18 to 49 years	50 to 64 years	≥65 years	Total
Blood	0	0	0	0	0	4	4
Pleural fluid	1	1	0	0	0	0	2
Total	1	1	0	0	0	4	6

Table 2. Number of IPD cases by age group and serotype of *Streptococcus pneumoniae* in this reporting period

Serotype	< 2 years	2 to 4 years	5 to 17 years	18 to 49 years	50 to 64 years	≥ 65 years	Total
3	0	1	0	0	0	2	3
19A	1	0	0	0	0	1	2
20	0	0	0	0	0	1	1
Total	1	1	0	0	0	4	6





Table 3. Serotypes of *Streptococcus pneumoniae* of reported IPD cases by year (including paediatric cases aged < 18 years shown in brackets)

;	Serotype	2015	2016	2017	2018	2019	2020	2021	2022	2023 (up to 31/3)	
	4	1 (0)	7 (0)	2 (0)	3 (0)	0 (0)	1 (0)	0 (0)	2 (0)	1 (0)	
1/13	6B	4 (1)	1 (0)	7 (2)	1 (0)	2 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Covered by PCV 7 / 10 / 13	9V	2 (0)	2 (0)	3 (0)	0 (0)	3 (0)	0 (0)	1 (0)	0 (0)	0 (0)	
, PCV	14	13 (0)	11 (0)	11 (2)	9 (1)	9 (0)	1 (0)	2 (0)	0 (0)	0 (0)	
red by	18C	0 (0)	1(1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Соче	19F	6 (0)	3 (0)	4 (0)	5 (2)	6 (0)	2 (0)	1 (0)	4 (0)	0 (0)	
	23F	6 (0)	4(1) 2(0)		4(1)	6 (0)	2 (0)	0 (0)	0 (0)	1 (0)	
by 13	1	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Covered by PCV10 / 13	5	0 (0)	0 (0)	1 (0)	1(1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Co PC	7 F	2 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
by nly	3	72 (23)	89 (29)	88 (31)	100 (32)	87 (32)	21 (4)	3 (0)	5 (0)	5 (2)	
Covered by PCV13 only	6A	3 (0)	1 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)	0 (0)	
Co PC	19A	8 (1)	13 (5)	16 (4)	11 (4)	11 (5)	4 (1)	1 (0) 4 (2)		2 (1)	
by 2	otypes covered 3vPPV but not by PCV13	22 (1)	20 (3)	14 (2)	19 (2)	23 (2)	3 (0)	3 (1)	2 (0)	1 (0)	
	on vaccine- ered serotypes	22 (2)	32 (8)	32 (2)	28 (5)	35 (5)	9 (1)	7 (1)	4(1)	3 (1)	
	Unknown	1 (0)	5 (1)	5 (1)	7 (2)	6 (3)	4 (0)	7 (1)	6 (1)	1 (1)	
	Total	162 (28)	189 (48)	186 (44)	189 (50)	189 (47)	47 (6)	25 (3)	28 (4)	14 (5)	

PCV: pneumococcal conjugate vaccine

23vPPV: 23-vlaent pneumococcal polysaccharide vaccine

Remarks:

♦ Figures are provisional and subject to adjustment.

♦ Table of pneumococcal capsular polysaccharides contained in pneumococcal vaccines for reference:

Serotypes	1	2	3	4	5	6A	6B	7F	8	9N	9V	10A	11A	12F	14	15B	17F	18C	19A	19F	20	22F	23F	33F
7-valent PCV				•			•				•				•			•		•			•	
10-valent PCV	•			•	•		•	•			•				•			•		•			•	
13-valent PCV	•		•	•	•	•	•	•			•				•			•	•	•			•	
23vPPV	•	•	•	•	•		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•

